Actinium Pharmaceuticals, Inc. current report, 11 June 2014

Full document

Business Context and Reporting Period

Company: Actinium Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 11, 2014
Event: Regulation FD Disclosure regarding a panel presentation at the NewYorkBIO-CONference (May 15, 2014) concerning the Company's lead product candidates, Iomab-B and Actimab-A.

Key Financial Metrics

The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The following financial details were disclosed:

  • Debt/Liabilities: The Company owes Memorial Sloan-Kettering Cancer Center (MSKCC), its largest shareholder, up to $249,463 in past fees and research support payments, with an obligation to pay by the end of 2014.
  • Intellectual Property Costs: The Company has licensing agreements with MSKCC and Abbvie involving license fees, research support payments, development milestones, and royalties on net sales.
  • Supply Agreements: Actinium-225 is sourced under an annual agreement with Oak Ridge National Laboratory expiring at the end of 2014, with an expectation of renewal.

Material Changes and Clinical Developments

The filing details significant clinical and strategic updates rather than financial changes:

  • Unmet Medical Need: A panel of leading hematologists/oncologists confirmed a significant unmet need for older patients (>55 years) with relapsed or refractory Acute Myeloid Leukemia (AML), noting poor historical outcomes for this demographic.
  • Paradigm Shift: Panelists discussed how Iomab-B could overturn the traditional paradigm that patients must achieve complete remission (CR) before undergoing hematopoietic stem cell transplantation (HSCT). Data suggests Iomab-B enables HSCT for patients who would otherwise be ineligible.
  • Survival Data: Panelists cited internal data indicating that Iomab-B conditioning could result in approximately 50% overall survival in poor-risk patients, with a one-year mortality rate of 20% (half that of traditional ablative regimens).

Guidance, Outlook, and Risks

Outlook and Trial Design

  • Pivotal Phase 3 Trial: The Company is preparing a single, pivotal, multicenter Phase 3 study for Iomab-B in refractory and relapsed AML patients over age 55.
  • Study Parameters: The trial is designed as a two-arm, randomized, controlled study with 150 patients (75 per arm). The primary endpoint is durable complete remission (lasting at least 6 months).
  • Control Arm: The control arm consists of "physician's choice" of chemotherapy, reflecting current best practices. Patients in the control arm achieving CR will proceed to HSCT; those who do not will cross over to the study arm.
  • Regulatory Path: An agreement with the FDA establishes that a successful pivotal Phase 3 study will lead to a Biologics License Application (BLA) submission.

    • Risks and Contingencies

    • Patent Expirations: U.S. patents for the antibody component of the product expire in 2014 (foreign patents have expired). The Company relies on trade secret protection and orphan drug exclusivities.
    • Supply Chain: The contract for actinium-225 supply expires at the end of 2014; failure to renew could impact development.
    • Financial Obligations: The Company must settle the $249,463 owed to MSKCC by the end of 2014.

    Investor Verification Checklist

    • Verify the Company's ability to fund the upcoming pivotal Phase 3 trial and settle the $249,463 debt to MSKCC by year-end 2014.
    • Confirm the renewal status of the actinium-225 supply agreement with Oak Ridge National Laboratory.
    • Review the specific intellectual property strategy regarding the 2014 expiration of U.S. antibody patents and reliance on trade secrets.
    • Monitor the enrollment progress and primary endpoint results of the 150-patient Phase 3 trial for Iomab-B.
    • Assess the clinical data supporting the claim that Iomab-B allows HSCT without prior complete remission.